Inventiva (NASDAQ:IVA) Shares Gap Down After Earnings Miss

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $5.48, but opened at $5.21. Inventiva shares last traded at $5.4650, with a volume of 223,688 shares changing hands.

The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.57). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $8.67 million.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. Truist Financial initiated coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. HC Wainwright set a $24.00 price objective on Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. UBS Group started coverage on Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Leerink Partners began coverage on Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Inventiva presently has a consensus rating of “Buy” and a consensus price target of $16.56.

Hedge Funds Weigh In On Inventiva

Institutional investors have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP acquired a new position in Inventiva in the fourth quarter valued at about $18,600,000. ADAR1 Capital Management LLC acquired a new stake in shares of Inventiva during the fourth quarter worth approximately $12,601,000. Millennium Management LLC increased its holdings in shares of Inventiva by 2,267.7% during the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after buying an additional 2,540,540 shares in the last quarter. UBS Group AG raised its stake in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares during the last quarter. Finally, SymBiosis Capital Partners LLC bought a new position in shares of Inventiva in the fourth quarter valued at approximately $12,090,000. 19.06% of the stock is owned by institutional investors.

Inventiva Stock Down 0.3%

The firm has a fifty day moving average price of $6.28 and a 200 day moving average price of $5.37.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.